CVS Group plc (FRA:4C9)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.04B -3.1% |
| Revenue (ttm) | 794.16M +7.1% |
| Net Income | 56.63M +997.8% |
| EPS | 0.79 +1,002.4% |
| Shares Out | n/a |
| PE Ratio | 18.30 |
| Forward PE | 13.94 |
| Dividend | 0.10 (0.64%) |
| Ex-Dividend Date | Nov 6, 2025 |
| Volume | n/a |
| Open | 15.10 |
| Previous Close | 14.90 |
| Day's Range | 15.10 - 15.10 |
| 52-Week Range | 12.60 - 17.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 24, 2026 |
About CVS Group
CVS Group plc, together with its subsidiaries, engages in veterinary, online pharmacy, and retail businesses in the United Kingdom and Australia. It operates through the Veterinary Practices, Laboratories, and Online Retail Business segments. The company is involved in animal veterinary practices and complementary veterinary diagnostic businesses. It also operates Animed Direct, an online retail business that sells prescription and non-prescription medicines, pet foods, and other pet care products, as well as an online dispensary. In addition, ... [Read more]
Financial Performance
In fiscal year 2025, CVS Group's revenue was 673.20 million, an increase of 5.40% compared to the previous year's 638.70 million. Earnings were 52.80 million, an increase of 751.61%.
Financial numbers in GBP Financial StatementsNews
CVS Group upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Sharanya Gajapathy upgraded CVS Group (CVSGF) to Overweight from Equal Weight with a price target of 1,630 GBp, up from 1,380 GBp. The firm cites “visibility and durability”…
CVS Group PLC To provide update on Capital Allocation and Returns Transcript
CVS Group PLC To provide update on Capital Allocation and Returns Transcript
CVS Group Q4 Earnings Call Highlights
CVS Group LON: CVSG said revenue for the financial year ended June 30 exceeded GBP 710 million, up 5.9% from the prior year, as the veterinary services provider used an investor presentation to reiter...
CVS Group Earnings Call Transcript: Q4 2026
Revenue grew 5.9% to over £710 million, with stable 20% EBITDA margin and strong cash conversion. Expansion in Australia is delivering accretive returns, and a £50 million share buyback reflects confidence in future growth. Leverage remains conservative at 1.63x.
CVS Group Earnings release: Q4 2026
CVS Group released its Q4 2026 earnings on July 23, 2026, summarizing the period's financial results.
CVS Group Slides: Investor presentation
CVS Group has posted slides in relation to its latest quarterly earnings report, which was published on July 23, 2026.
Converium Capital Sends Letter to CVS Group Board Highlighting Company's Undervaluation and Urging £100 Million Share Buyback
MONTREAL--(BUSINESS WIRE)--Converium Capital Inc. (“Converium”), which manages funds that own shares of CVS Group plc (LSE: CVSG) (“CVS Group” or the “Company”), today announced that it has sent a let...
UK's CVS Group CEO to step down after 7 years at the helm
British veterinary services provider CVS Group said on Monday CEO Richard Fairman plans to retire after seven years in the role.
CVS Group initiated with an Equal Weight at Barclays
Barclays initiated coverage of CVS Group (CVSGF) with an Equal Weight rating and 1,340 GBp price target The firm cites competitive dynamics in the UK merger market and the weak…
CVS Group Earnings Call Transcript: H1 2026
Revenue and EBITDA grew despite inflation and weak UK consumer confidence, with strong margin performance in Australia and ongoing disciplined M&A. Most CMA compliance measures are already in place, and further margin improvement is expected as cost pressures ease.
CVS Group Quarterly report: H1 2026
CVS Group has published its H1 2026 quarterly earnings report on February 26, 2026.
CVS Group Slides: H1 2026
CVS Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 26, 2026.
CVS Group Earnings Call Transcript: H1 2026
Revenue grew 5.8% year-over-year to GBP 356.9 million, with adjusted EBITDA up 3.9% and strong cash flow supporting continued investment. Australia now contributes 10% of revenue and 15% of EBITDA, while the group maintains leverage well below its target ceiling.
CVS Group Quarterly report: H1 2026
CVS Group has published its H1 2026 quarterly earnings report on February 26, 2026.
CVS Group Slides: H1 2026
CVS Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 26, 2026.
CVS Group Earnings release: Q2 2026
CVS Group released its Q2 2026 earnings on January 23, 2026, summarizing the period's financial results.
CVS Group Earnings release: Trading Update
CVS Group released its earnings on November 18, 2025, summarizing the period's financial results.
UK's CVS Group plans Main Market move, approves near $27 million buyback
Veterinary services provider CVS Group said on Friday it plans to move its listing from the Alternative Investment Market to the London Stock Exchange's Main Market, while also approving a new 20 mill...
CVS Group Transcript: Investor Update
Revenue rose 5.4% to £673.2m and adjusted EBITDA grew 9.4%, with strong cash generation and leverage reduced to 1.18x. Expansion in Australia continues, UK acquisitions are set to resume post-CMA, and medium-term like-for-like growth guidance is 4–8%.
CVS Group Earnings Call Transcript: H2 2025
Revenue grew 5.4% to £673.2m, with adjusted EBITDA up 9.4% and margin at 20%. Australian expansion continued, and UK operations improved, with strong cash flow and reduced leverage. Confident in medium-term 4%-8% growth, supported by efficiency gains and selective acquisitions.
CVS Group Annual report: H2 2025
CVS Group has published its H2 2025 annual report on October 7, 2025.
CVS Group Annual report: H2 2025
CVS Group has published its H2 2025 annual report on October 7, 2025.
CVS Group Slides: H2 2025
CVS Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on October 7, 2025.
CVS Group Earnings Call Transcript: H2 2025
Revenue grew 5.4% to GBP 673.2 million, with Adjusted EBITDA up 9.4% and margin at 20%. Strong cash flow, reduced leverage, and continued expansion in Australia position the group for further growth, despite ongoing CMA investigation and sector headwinds.
CVS Group Annual report: H2 2025
CVS Group has published its H2 2025 annual report on October 7, 2025.